HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bloch, W. Articles by Mehlhorn, U. Search for Related Content PubMed PubMed Citation Articles by Bloch, W. Articles by Mehlhorn, U. Related Collections Myocardial protection

J Thorac Cardiovasc Surg 2004;128:323-324
© 2004 The American Association for Thoracic Surgery

Letter to the editor

Poly–adenosine diphosphate–ribose polymerase inhibition for myocardial protection: Pathophysiologic and physiologic considerations

^a Institute I for Anatomy, University of Cologne, Cologne, Germany
^b Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany

The first 20% of the full text of this article appears below.

To the Editor:

We read with great interest the article by Szabo and associates¹ in which they reported the use of state-of-the-art animal instrumentation and molecular biologic techniques to demonstrate that poly–adenosine diphosphate–ribose polymerase (PARP) inhibition protects against myocardial and endothelial reperfusion injury after crystalloid cardioplegic arrest. In the discussion, they attributed this primarily to energy-saving effects, because activation and (more importantly) activity of the enzyme PARP require energy.¹ However, they did not address the physiologic functions . . . [Full Text of this Article]